Don’t disagree Parko, To add to your comments:

Whilst Jayne spoke freely and with obvious knowledge on the woes of ASX listed Pacific Edge (Bladder cancer testing) and Rhythm Biosciences (Colon cancer testing), she ran dead on any feedback on the most relevant ASX listed company IIQ. More generally when Andrew asked about the overall competitive landscape it was just a talk around. (What else would you expect!)

Similarly when asked about the financing it was not at all informative.  No doubt Jayne has her reasons for this. As at the 31/12/24 there was $6.3m cash and tax receivables.  Very roughly they appear to be going through about $2m a quarter.  And with a ramp up needed to get to generating revenue by the end of the calendar year, I would think a capital raising could not be ruled out.  

On a more positive note management appears to have a great local background in breast cancer diagnosis, and Janye made a point of telling the connections they have with various politicians.  Their strategy seems a plausible one. That is for the test to be used as an adjunct to the accepted though not infallible current standard of testing, the mammogram. Their focus being initially Sydney and Melbourne markets. . 

Jayne provided evidence that patients would pay an additional $300 for the greater security the complimentary Breastest test would provide.

Lets say they get their projected 20,000 - 40,000 tests next year at $300/test this is around $6m -$12m of revenue. Not inconsequential, however no guidance was given on what the margin might look like.     

All plausible, however who ultimately wins, and this is a world-wide contest, will be the company who quickly gets the regulatory approvals, gets to scale and can demonstrate the best science. And who knows who that will be.